ProstaScore®

An accurate tissue-based test

to predict non-evolutive localized prostate cancer (LPCa)

Description

- Use of next generation sequencing (NGS) technology for gene expression analysis

- A sensitive quantification of RNA biomarkers of interest

- A software for an accurate rendering of results

Clinical validation

Patent

EP18305060, 2018: Molecular signature and use thereof for the identification of indolent prostate cancer.

Publication

Kamoun A, Cancel-Tassin G, Formont g, elarouci N, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology. 2018 August 1814-1821.

https://doi.org/10.1093/annonc/mdy224

Abstract

Evaluation of ProstaScore™ and Magnetic Resonance Imaging for preoperative prediction of Lymph Node Involvement determined by Extended Lymph Node Dissection. 41^st Annual EAU Congress (EAU26)-London on 13-16 March, 2026.